Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Radiation Oncology
Published in: Radiation Oncology 1/2019

Open Access 01-12-2019 | NSCLC | Research

Comparison of the outcomes of stereotactic body radiotherapy versus surgical treatment for elderly (≥70) patients with early-stage non-small cell lung cancer after propensity score matching

Authors: Baiqiang Dong, Jin Wang, Xuan Zhu, Yuanyuan Chen, Yujin Xu, Kainan Shao, Lei Zheng, Hangjie Ying, Ming Chen, Jianping Cao

Published in: Radiation Oncology | Issue 1/2019

Login to get access

Abstract

Background

The optimal treatment for elderly patients with early-stage non-small cell lung cancer (NSCLC) remains inconclusive. Previous studies have shown that stereotactic body radiotherapy (SBRT) provides encouraging local control though higher incidence of toxicity in elderly than younger populations. The objective of this study was to compare the outcomes of SBRT and surgical treatment in elderly patients with clinical stage I-II NSCLC.

Methods

This retrospective analysis included 205 patients aged ≥70 years with clinical stage I NSCLC who underwent SBRT or surgery at Zhejiang Cancer Hospital (Hangzhou, China) from January 2012 to December 2017. A propensity score matching analysis was performed between the two groups. In addition, we compared outcomes and related toxicity in both study arms.

Results

Each group included 35 patients who met the inclusion criteria. Median follow-up was 50.1 (0.8–74.4) months for surgery and 35.5 (11.5–71.4) months for SBRT. The rate of cancer-specific survival was similar between the two treatment arms (p = 0.958). In patients who underwent surgery, the corresponding 3- and 5-year cancer-specific survival rates were 85.3 and 81.7%, respectively. In those who received radiotherapy, these rates were 91.3 and 74.9%, respectively. Moreover, the 3- and 5-year locoregional control in patients who underwent surgery were 90.0 and 80.0%, respectively. In those who received radiotherapy, these rates were 91.1 and 84.1%, respectively. Notably, the observed differences in progression-free survival were not statistically significant (p = 0.934). In the surgery group, grade 1–2 complications were observed in eleven patients (31%). One patient died due to perioperative infection within 30 days following surgery. There was no grade 3–5 toxicity observed in the SBRT group.

Conclusions

The outcomes of surgery and SBRT in elderly patients with early-stage NSCLC were similar.
Literature
1.
Aberle DR, DeMello S, Berg CD, Black WC, Brewer B, Church TR, Clingan KL, Duan F, Fagerstrom RM, Gareen IF, et al. Results of the two incidence screenings in the National Lung Screening Trial. N Engl J Med. 2013;369(10):920–31.PubMedPubMedCentralCrossRef
2.
Darling GE, Allen MS, Decker PA, Ballman K, Malthaner RA, Inculet RI, Jones DR, McKenna RJ, Landreneau RJ, Putnam JB Jr. Number of lymph nodes harvested from a mediastinal lymphadenectomy: results of the randomized, prospective American College of Surgeons oncology group Z0030 trial. Chest. 2011;139(5):1124–9.PubMedCrossRef
3.
Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer study group. Ann Thorac Surg. 1995;60(3):615–22 discussion 622-613.PubMedCrossRef
4.
Nguyen NP, Godinez J, Shen W, Vinh-Hung V, Gorobets H, Thariat J, Ampil F, Vock J, Karlsson U, Chi A. Is surgery indicated for elderly patients with early stage nonsmall cell lung cancer, in the era of stereotactic body radiotherapy? Medicine. 2016;95(43):e5212.PubMedPubMedCentralCrossRef
5.
Navarria P, Ascolese AM, Mancosu P, Alongi F, Clerici E, Tozzi A, Iftode C, Reggiori G, Tomatis S, Infante M, et al. Volumetric modulated arc therapy with flattening filter free (FFF) beams for stereotactic body radiation therapy (SBRT) in patients with medically inoperable early stage non small cell lung cancer (NSCLC). Radiother Oncol. 2013;107(3):414–8.PubMedCrossRef
6.
Vansteenkiste J, Crino L, Dooms C, Douillard JY, Faivre-Finn C, Lim E, Rocco G, Senan S, Van Schil P, Veronesi G, et al. 2nd ESMO consensus conference on lung Cancer: early-stage non-small-cell lung cancer consensus on diagnosis, treatment and follow-up. Ann Oncol. 2014;25(8):1462–74.PubMedCrossRef
7.
Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, Groen HJ, McRae SE, Widder J, Feng L, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. The Lancet Oncology. 2015;16(6):630–7.PubMedPubMedCentralCrossRef
8.
Palma DA, Senan S. Improving outcomes for high-risk patients with early-stage non-small-cell lung cancer: insights from population-based data and the role of stereotactic ablative radiotherapy. Clinical lung cancer. 2013;14(1):1–5.PubMedCrossRef
9.
Timmerman RD, Paulus R, Pass HI, Gore EM, Edelman MJ, Galvin J, Straube WL, Nedzi LA, McGarry RC, Robinson CG, et al. Stereotactic body radiation therapy for operable early-stage lung Cancer: findings from the NRG oncology RTOG 0618 trial. JAMA oncology. 2018;4(9):1263–6.PubMedPubMedCentralCrossRef
10.
Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, Karasawa K, Hayakawa K, Niibe Y, Takai Y, et al. Stereotactic body radiotherapy (SBRT) for operable stage I non-small-cell lung cancer: can SBRT be comparable to surgery? Int J Radiat Oncol Biol Phys. 2011;81(5):1352–8.PubMedCrossRef
11.
Paul S, Lee PC, Mao J, Isaacs AJ, Sedrakyan A. Long term survival with stereotactic ablative radiotherapy (SABR) versus thoracoscopic sublobar lung resection in elderly people: national population based study with propensity matched comparative analysis. BMJ (Clinical research ed). 2016;354:i3570.
12.
Shirvani SM, Jiang J, Chang JY, Welsh J, Likhacheva A, Buchholz TA, Swisher SG, Smith BD. Lobectomy, sublobar resection, and stereotactic ablative radiotherapy for early-stage non-small cell lung cancers in the elderly. JAMA surgery. 2014;149(12):1244–53.PubMedPubMedCentralCrossRef
13.
Palma D, Senan S. Stereotactic radiation therapy: changing treatment paradigms for stage I nonsmall cell lung cancer. Curr Opin Oncol. 2011;23(2):133–9.PubMedCrossRef
14.
Palma D, Visser O, Lagerwaard FJ, Belderbos J, Slotman B, Senan S. Treatment of stage I NSCLC in elderly patients: a population-based matched-pair comparison of stereotactic radiotherapy versus surgery. Radiother Oncol. 2011;101(2):240–4.PubMedCrossRef
15.
De Leyn P, Lardinois D, Van Schil PE, Rami-Porta R, Passlick B, Zielinski M, Waller DA, Lerut T, Weder W. ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer. Eur J Cardiothorac Surg. 2007;32(1):1–8.PubMedCrossRef
16.
Chen G, Dong B, Shan G, Zhang X, Tang H, Li Y, Wang Z, Xu W, Xu G, Yan G, et al. Choice of immobilization of stereotactic body radiotherapy in lung tumor patient by BMI. BMC Cancer. 2019;19(1):583.PubMedPubMedCentralCrossRef
17.
Dong B, Wang J, Xu Y, Hu X, Shao K, Li J, Zheng L, Chen M, Cao J. Comparison of the efficacy of stereotactic body radiotherapy versus surgical treatment for early-stage non-small cell lung Cancer after propensity score matching. Transl Oncol. 2019;12(8):1032–7.PubMedPubMedCentralCrossRef
18.
Matsuo Y, Nakamoto Y, Nagata Y, Shibuya K, Takayama K, Norihisa Y, Narabayashi M, Mizowaki T, Saga T, Higashi T, et al. Characterization of FDG-PET images after stereotactic body radiation therapy for lung cancer. Radiother Oncol. 2010;97(2):200–4.PubMedCrossRef
19.
Huang K, Dahele M, Senan S, Guckenberger M, Rodrigues GB, Ward A, Boldt RG, Palma DA. Radiographic changes after lung stereotactic ablative radiotherapy (SABR)--can we distinguish recurrence from fibrosis? A systematic review of the literature. Radiother Oncol. 2012;102(3):335–42.PubMedCrossRef
20.
Gajra A, Akbar SA, Din NU. Management of Lung Cancer in the elderly. Clin Geriatr Med. 2016;32(1):81–95.PubMedCrossRef
21.
Schneider BJ, Daly ME, Kennedy EB, Antonoff MB, Broderick S, Feldman J, Jolly S, Meyers B, Rocco G, Rusthoven C, et al. Stereotactic body radiotherapy for early-stage non-small-cell lung Cancer: American Society of Clinical Oncology endorsement of the American Society for Radiation Oncology evidence-based guideline. J Clin Oncol. 2018;36(7):710–9.PubMedCrossRef
22.
Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Johnstone D, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. Jama. 2010;303(11):1070–6.PubMedPubMedCentralCrossRef
23.
Timmerman RD, Hu C, Michalski JM, Bradley JC, Galvin J, Johnstone DW, Choy H. Long-term results of stereotactic body radiation therapy in medically inoperable stage I non-small cell lung Cancer. JAMA oncology. 2018;4(9):1287–8.PubMedPubMedCentralCrossRef
24.
Shirvani SM, Jiang J, Chang JY, Welsh JW, Gomez DR, Swisher S, Buchholz TA, Smith BD. Comparative effectiveness of 5 treatment strategies for early-stage non-small cell lung cancer in the elderly. Int J Radiat Oncol Biol Phys. 2012;84(5):1060–70.PubMedPubMedCentralCrossRef
25.
Robinson CG, DeWees TA, El Naqa IM, Creach KM, Olsen JR, Crabtree TD, Meyers BF, Puri V, Bell JM, Parikh PJ, et al. Patterns of failure after stereotactic body radiation therapy or lobar resection for clinical stage I non-small-cell lung cancer. J Thorac Oncol. 2013;8(2):192–201.PubMedCrossRef
26.
Crabtree TD, Puri V, Robinson C, Bradley J, Broderick S, Patterson GA, Liu J, Musick JF, Bell JM, Yang M, et al. Analysis of first recurrence and survival in patients with stage I non-small cell lung cancer treated with surgical resection or stereotactic radiation therapy. J Thorac Cardiovasc Surg. 2014;147(4):1183–91 discussion 1191-1182.PubMedPubMedCentralCrossRef
27.
Chen H, Laba JM, Boldt RG, Goodman CD, Palma DA, Senan S, Louie AV. Stereotactic ablative radiation therapy versus surgery in early lung Cancer: a meta-analysis of propensity score studies. Int J Radiat Oncol Biol Phys. 2018;101(1):186–94.PubMedCrossRef
28.
Grills IS, Mangona VS, Welsh R, Chmielewski G, McInerney E, Martin S, Wloch J, Ye H, Kestin LL. Outcomes after stereotactic lung radiotherapy or wedge resection for stage I non-small-cell lung cancer. J Clin Oncol. 2010;28(6):928–35.PubMedCrossRef
29.
Mokhles S, Verstegen N, Maat AP, Birim O, Bogers AJ, Mokhles MM, Lagerwaard FJ, Senan S, Takkenberg JJ. Comparison of clinical outcome of stage I non-small cell lung cancer treated surgically or with stereotactic radiotherapy: results from propensity score analysis. Lung cancer (Amsterdam, Netherlands). 2015;87(3):283–9.CrossRef
30.
Zhang B, Zhu F, Ma X, Tian Y, Cao D, Luo S, Xuan Y, Liu L, Wei Y. Matched-pair comparisons of stereotactic body radiotherapy (SBRT) versus surgery for the treatment of early stage non-small cell lung cancer: a systematic review and meta-analysis. Radiother Oncol. 2014;112(2):250–5.PubMedCrossRef
31.
Verstegen NE, Oosterhuis JW, Palma DA, Rodrigues G, Lagerwaard FJ, van der Elst A, Mollema R, van Tets WF, Warner A, Joosten JJ, et al. Stage I-II non-small-cell lung cancer treated using either stereotactic ablative radiotherapy (SABR) or lobectomy by video-assisted thoracoscopic surgery (VATS): outcomes of a propensity score-matched analysis. Ann Oncol. 2013;24(6):1543–8.PubMedCrossRef
32.
Varlotto J, Fakiris A, Flickinger J, Medford-Davis L, Liss A, Shelkey J, Belani C, DeLuca J, Recht A, Maheshwari N, et al. Matched-pair and propensity score comparisons of outcomes of patients with clinical stage I non-small cell lung cancer treated with resection or stereotactic radiosurgery. Cancer. 2013;119(15):2683–91.PubMedCrossRef
33.
Solda F, Lodge M, Ashley S, Whitington A, Goldstraw P, Brada M. Stereotactic radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; systematic review and comparison with a surgical cohort. Radiother Oncol. 2013;109(1):1–7.PubMedCrossRef
34.
Guckenberger M, Kestin LL, Hope AJ, Belderbos J, Werner-Wasik M, Yan D, Sonke JJ, Bissonnette JP, Wilbert J, Xiao Y, et al. Is there a lower limit of pretreatment pulmonary function for safe and effective stereotactic body radiotherapy for early-stage non-small cell lung cancer? J Thorac Oncol. 2012;7(3):542–51.PubMedCrossRef
35.
Alexander M, Wolfe R, Ball D, Conron M, Stirling RG, Solomon B, MacManus M, Officer A, Karnam S, Burbury K, et al. Lung cancer prognostic index: a risk score to predict overall survival after the diagnosis of non-small-cell lung cancer. Br J Cancer. 2017;117(5):744–51.PubMedPubMedCentralCrossRef
36.
Haasbeek CJ, Lagerwaard FJ, Antonisse ME, Slotman BJ, Senan S. Stage I nonsmall cell lung cancer in patients aged > or =75 years: outcomes after stereotactic radiotherapy. Cancer. 2010;116(2):406–14.PubMedCrossRef
37.
Ricardi U, Filippi AR, Guarneri A, Giglioli FR, Ciammella P, Franco P, Mantovani C, Borasio P, Scagliotti GV, Ragona R. Stereotactic body radiation therapy for early stage non-small cell lung cancer: results of a prospective trial. Lung cancer (Amsterdam, Netherlands). 2010;68(1):72–7.CrossRef
38.
Truong MT, Ko JP, Rossi SE, Rossi I, Viswanathan C, Bruzzi JF, Marom EM, Erasmus JJ. Update in the evaluation of the solitary pulmonary nodule. Radiographics. 2014;34(6):1658–79.PubMedCrossRef
39.
Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF, Senan S. Outcomes of stereotactic ablative radiotherapy in patients with potentially operable stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2012;83(1):348–53.PubMedCrossRef
40.
Belgers EH, Siebenga J, Bosch AM, van Haren EH, Bollen EC. Complete video-assisted thoracoscopic surgery lobectomy and its learning curve. A single center study introducing the technique in the Netherlands. Interact Cardiovasc Thorac Surg. 2010;10(2):176–80.PubMedCrossRef
41.
Donington JS. Point: are limited resections appropriate in non-small cell lung cancer? Yes. Chest. 2012;141(3):588–90.PubMedCrossRef
42.
Yerokun BA, Yang CJ, Gulack BC, Li X, Mulvihill MS, Gu L, Wang X, Harpole DH, D'Amico TA, Berry MF, et al. A national analysis of wedge resection versus stereotactic body radiation therapy for stage IA non-small cell lung cancer. J Thorac Cardiovasc Surg. 2017;154(2):675–86 e674.PubMedCrossRef
43.
Sakurai H, Asamura H. Sublobar resection for early-stage lung cancer. Translational lung cancer research. 2014;3(3):164–72.PubMedPubMedCentral
44.
Paul S, Altorki NK, Sheng S, Lee PC, Harpole DH, Onaitis MW, Stiles BM, Port JL, D'Amico TA. Thoracoscopic lobectomy is associated with lower morbidity than open lobectomy: a propensity-matched analysis from the STS database. J Thorac Cardiovasc Surg. 2010;139(2):366–78.PubMedCrossRef
45.
Ceppa DP, Kosinski AS, Berry MF, Tong BC, Harpole DH, Mitchell JD, D'Amico TA, Onaitis MW. Thoracoscopic lobectomy has increasing benefit in patients with poor pulmonary function: a Society of Thoracic Surgeons database analysis. Ann Surg. 2012;256(3):487–93.PubMedCrossRef
46.
Yu JB, Soulos PR, Cramer LD, Decker RH, Kim AW, Gross CP. Comparative effectiveness of surgery and radiosurgery for stage I non-small cell lung cancer. Cancer. 2015;121(14):2341–9.PubMedCrossRef
47.
Sandhu AP, Lau SK, Rahn D, Nath SK, Kim D, Song WY, Gulaya S, Fuster MM, Bazhenova L, Mundt AJ. Stereotactic body radiation therapy in octogenarians with stage I lung cancer. Clinical lung cancer. 2014;15(2):131–5.PubMedCrossRef
48.
Leeman JE, Rimner A, Montecalvo J, Hsu M, Zhang Z, von Reibnitz D, Panchoo K, Yorke E, Adusumilli PS, Travis W, et al. Histologic subtype in Core lung biopsies of early-stage lung adenocarcinoma is a prognostic factor for treatment response and failure patterns after stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2017;97(1):138–45.PubMedCrossRef
49.
Woody NM, Stephans KL, Andrews M, Zhuang T, Gopal P, Xia P, Farver CF, Raymond DP, Peacock CD, Cicenia J, et al. A histologic basis for the efficacy of SBRT to the lung. J Thorac Oncol. 2017;12(3):510–9.PubMedCrossRef
50.
Zhang Z, Zhang Y, Feng H, Yao Z, Teng J, Wei D, Liu D. Is video-assisted thoracic surgery lobectomy better than thoracotomy for early-stage non-small-cell lung cancer? A systematic review and meta-analysis. Eur J Cardiothorac Surg. 2013;44(3):407–14.PubMedCrossRef
51.
Onishi H, Shirato H, Nagata Y, Hiraoka M, Fujino M, Gomi K, Niibe Y, Karasawa K, Hayakawa K, Takai Y, et al. Hypofractionated stereotactic radiotherapy (HypoFXSRT) for stage I non-small cell lung cancer: updated results of 257 patients in a Japanese multi-institutional study. J Thorac Oncol. 2007;2(7 Suppl 3):S94–100.PubMedCrossRef
52.
Olsen JR, Robinson CG, El Naqa I, Creach KM, Drzymala RE, Bloch C, Parikh PJ, Bradley JD. Dose-response for stereotactic body radiotherapy in early-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2011;81(4):e299–303.PubMedCrossRef
53.
Koshy M, Malik R, Weichselbaum RR, Sher DJ. Increasing radiation therapy dose is associated with improved survival in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2015;91(2):344–50.PubMedCrossRef
Metadata
Title
Comparison of the outcomes of stereotactic body radiotherapy versus surgical treatment for elderly (≥70) patients with early-stage non-small cell lung cancer after propensity score matching
Authors
Baiqiang Dong
Jin Wang
Xuan Zhu
Yuanyuan Chen
Yujin Xu
Kainan Shao
Lei Zheng
Hangjie Ying
Ming Chen
Jianping Cao
Publication date
01-12-2019
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2019
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/s13014-019-1399-5

Other articles of this Issue 1/2019

Radiation Oncology 1/2019 Go to the issue

Research

DCE and DSC perfusion MRI diagnostic accuracy in the follow-up of primary and metastatic intra-axial brain tumors treated by radiosurgery with cyberknife

Research

Association between the location of transposed ovary and ovarian dose in patients with cervical cancer treated with postoperative pelvic radiotherapy

Research

Impact of patient and treatment characteristics on heart and lung dose in adjuvant radiotherapy for left-sided breast cancer

Research

Single isocenter stereotactic radiosurgery for patients with multiple brain metastases: dosimetric comparison of VMAT and a dedicated DCAT planning tool

Methodology

Methodology paper: a novel phantom setup for commissioning of scanned ion beam delivery and TPS

Research

Feasibility of hybrid TomoHelical- and TomoDirect-based volumetric gradient matching technique for total body irradiation